SPRUCE BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
SPRB$49.34+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Additional · Accumulated Other · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | |||||||
| Shares · Amount · Capital · Loss · Deficit · Equity | |||||||
| Balance as of January 1, 2022 | 23,491,881 | $3 | $214,685 | $(184) | $(103,133) | $111,371 | |
| Exercise of common stock options | 992 | — | 2 | — | — | 2 | |
| Issuance of common stock related to employee stock purchase plan | 66,299 | — | 76 | — | — | 76 | |
| Issuance of common stock related to vesting of restricted stock units, net of tax withholdings | 41,832 | — | (40) | — | (40) | ||
| Stock-based compensation | — | — | 3,631 | — | — | 3,631 | |
| Unrealized loss on available for sale securities | — | — | — | (374) | — | (374) | |
| Net loss | — | — | — | — | (46,180) | (46,180) | |
| Balance as of December 31, 2022 | 23,601,004 | 3 | 218,354 | (558) | (149,313) | 68,486 | |
| Exercise of pre-funded warrants | 800,000 | — | 8 | — | — | 8 | |
| Exercise of common stock options | 54 | — | 1 | — | — | 1 | |
| Issuance of common stock related to employee stock purchase plan | 162,791 | — | 169 | — | — | 169 | |
| Issuance of common stock related to vesting of restricted stock units, net of tax withholdings | 349,983 | — | (311) | — | — | (311) | |
| Issuance of common stock and warrants, net of offering costs of $2,721 | 16,116,000 | 1 | 50,894 | — | — | 50,895 | |
| Stock-based compensation | — | — | 4,622 | — | — | 4,622 | |
| Unrealized gain on available for sale securities | — | — | — | 558 | — | 558 | |
| Net loss | — | — | — | — | (47,919) | (47,919) | |
| Balance as of December 31, 2023 | 41,029,832 | $4 | $273,737 | $— | $(197,232) | $76,509 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.